Lrp16基因在白血病细胞系及白血病患者骨髓中的表达及其临床意义  

Lrp16 Gene Expression in Leukemia Cell Lines and Bone Marrow Cells of Leukemia Patients and Its Clinical Implication

作　　者：杨波[1] 迟小华[2] 卢学春[1] 韩为东[3] 于力[4] 楼方定[4] 

机构地区：[1]解放军总医院老年血液科,北京100853 [2]解放军第262医院药剂科,北京100800 [3]解放军总医院基础医学研究所免疫教研室,北京100853 [4]解放军总医院血液科,北京100853

出　　处：《中国实验血液学杂志》2009年第4期857-860,共4页Journal of Experimental Hematology

基　　金：国家自然科学基金资助项目(编号30772597);国家自然科学基金资助项目(编号30873086)

摘　　要：本研究分析lrp16基因在白血病细胞系及白血病患者骨髓中的表达,探讨lrp16基因与白血病发生、发展的关系。采用逆转录聚合酶链式反应(RT-PCR)技术检测lrp16基因mRNA在4种白血病细胞系及115例白血病患者骨髓中的表达水平,并结合患者临床特征分析lrp16基因在白血病发生、发展中的作用。4种白血病细胞系包括慢性髓系白血病细胞系K562、急性早幼粒细胞白血病细胞系HL-60、急性淋巴细胞白血病细胞系MOLT4及具有单核细胞特征的白血病细胞系U937。结果表明:lrp16基因在K562、HL-60、MOLT4及U9374种细胞系中均表达。lrp16基因在急性髓系白血病患者表达阳性率为38%(16/42),其中完全缓解者表达阳性率为13%(4/30),未缓解者为100%(12/12);在急性淋巴细胞白血病患者表达阳性率为38%(10/26),其中完全缓解者阳性率为16%(3/18),未缓解者为87%(7/8);在慢性髓系白血病患者表达阳性率为36%(9/25),其中完全缓解者阳性率为20%(4/20),未缓解者为100%(5/5);在慢性淋巴细胞白血病患者表达阳性率为31%(7/22),其中完全缓解者阳性率为11%(2/17),未缓解者为100%(5/5)。lrp16基因表达在各种白血病亚型之间无差异,但各亚型中完全缓解者与未缓解者之间存在显著差异(p<0.001)。结论:lrp16基因是一个白血病癌基因,与白血病的发生、发展密切相关,有可能作为临床白血病治疗疗效的评价指标。This study was purposed to investigate lrp16 gene expression in leukemia cell lines and bone marrow cells of leukemia patients and explore the relationship between lrp16 gene expression and development of leukemia. Reverse transcriptase-polymerase chain reaction （RT-PCR） was employed to test the lrp16 mRNA expression in 4 leukemia cell lines, including K562 （CML）, HL-60 （APL）, MOLT4（ALL） and U937 cell lines, as well as in bone marrow-derived cells from 115 patients with leukemia. The effect of lrp16 gene expression on genesis and progression of leukemia was analyzed according to clinicopathological features. The results indicated that positive expression of lrp16 mRNA was found in all 4 leukemia cell lines. For leukemia patients, the positive expression rate of lrp16 mRNA in all AML patients was 38% （16/42）, in which the positive rates in AML patients with complete remission （CR） and AML pateints without remission were 13% （4/30） and 100% （12/12） respectively. The positive expression rate of lrpl6 mRNA in ALL patients was 38% （ 10/26）, in which the positive rate in ALL patients with CR and ALL patients without remission were 16 % （3/18） and 87 % （7/8） respectively. The positive expression rate of lrpl 6 mRNA in CML patients was 36% （ 9/25 ）, in which the positve rates in CML patients with CR and CML patients without remission were 20% （4/20） and 100% （5/5） respectively. The positive rate of lrp16 mRNA in CLL patients was 31% （7/22）, in which the possitie rate in CLL patients with CR and CLL patients without rimission were 11% （2/17） and 100% （5/5） respectively. There was no difference of lrp16 gene expression between leukemia subtypes, but there was statistical significant difference in lrp16 gene expression between CR patients and non CR patients （p 〈 0. 001 ）. It is concluded that the lrp16 gene is a leukemic oncogene and closely relates to genesis and progression of leukemia, which may be an incicator for evaluating clinical efficacy of

关 键 词：LRP16基因 白血病 白血病细胞系 

分 类 号：R733.7[医药卫生—肿瘤]